IA "Non-Event" Jan. 30th That Could Quickly Spell Bad News

New Post Public Reply Private Reply Replies (0) Message Board
BULL2222
IA "Non-Event" Jan. 30th That Could Quickly Spell Bad News For Kandi Technologies Short Sellers. [View instapost]
Serrco- Since you asked; Yes I can "explain to everyone" about my discussion with Kewa Luo about you and "your" supposed self written articles.

We discussed several things.

Aside from what I already said about the disbelief that both Company SEC counsel and I have about "your" two articles written and researched by the same person, we went on to discuss:

She mentioned how pleased she and Mr. Hu were that investors could see through and reject your desperate attempt to confuse with ignorant accusations against the JV and Mr. Hu while totally ignoring that fact that Geely and its CEO Li Shufu is a 50% partner. This confirmed by the strong stock performance after each each article.

I agreed and reminded her what the real goal of "attack articles" were and that is to try to create selling from less knowledgeable investors or bring in new hot money short sellers so the author and friends could use the drop to try to cover their shorts.

I reminded her that the reason we have seen such a recent pick-up in these articles is based on all of the now obvious Government support of KNDI. Short sellers now realize that they miscalculated how an obscure "go-cart" manufacturer could so quickly jump to its public uncontested #1 position in China EVs and enamor the highest level of Government Officials in CHINA to not only support KNDI's business models, but also endorse it to local Governments along with all its 1.3 billion people. For you to try to convince intelligent investors that Hu and Shufu are running a scam against their own National Government, a Government that has been know to execute fraudulent CEO's is farcical to say the least.

I further told her that no matter what these attack writers try to say in their articles, they made an early speculative bet against the company and they now know full well that were wrong. Of all Countries, YOU DON't BET AGAINST THE WILL AND SUPPORT OF THE PRC GOVERNMENT.

I told her there is an old adage in the market; "You make a stock look weaker if you want to Buy and stronger if you want to sell". Something Jim Cramer revealed in a TV interview titled;

"Jim Cramer reveals dirty tricks short sellers use to manipulate stock prices down"
http://bit.ly/1nMb9U1


We also discussed how surprising it was that a third year law student could find the time to spend 20 hours a day monitoring, contributing and insistently commenting with the same debunked unfounded allegations on any Social Media Venue accessible and still manage to maintain you studies.

I told her since your ranting has become so humorous that as long as you were not being disrespectful, I was leaving your comments up on this blog to show investors how silly you have become. But I also reminded her that "desperate people take desperate measures" when they are trapped.

I also told her that for your sake, I hoped, if you managed to make it into legal practice that you not choose any business related specialty because all of your articles and rants will remain on the Internet forever. Any big ticket prospective client will easily find what you have been recently wasting your time on 20 hours a day and the very poor arguments you have made trying to defend your position. This will particularly be exacerbated in a few years when KNDI will be a Wall Street darling with $10+ billion market cap company.

Judgement is EVERYTHING in the selection process for a lawyer and at least with KNDI shareholders, already you have been "weighed measured and found lacking"


BTW, I am not a lawyer, but even I know that a good lawyer NEVER asks a "witness" an open ended question in public unless he knows what that witness is going to say. If what I am saying here offends you, you have only yourself to blame for asking me:

Quote:
"Please, Arthur, can you explain to everyone the context of the conversation between you and Kandi IR, Kewa Luo?"

Kandi Technologies Group Inc (KNDI) Stock Research Links

KNDI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

illycaffè's B Corp™ Recertification Reflects Bold Commitment

Updated Category News Views 2

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Continue Reading
Stravito's MCP Server Revolutionizes AI in Business

Updated Category News Views 6

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...

Continue Reading
Clarius Named in TIME's Top HealthTech 2026 Again

Updated Category News Views 6

When a company gets the nod from TIME two years in a row, you know they’re not just tinkering with gadgets—they’re changing the game. Clarius Mobile Health, with its cutting-edge wireless ultrasound tech, has cemented its place in TIME's World's Top HealthTech Companies of 2026. Last I checked, repeating this kind of recognition never comes easy in such a fiercely...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 5

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
Wrensilva Unveils Studio Console in White Oak

Updated Category News Views 4

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

Continue Reading
PhoenixAI and Cloudera's Strategic Partnership Shifts Data Landscape

Updated Category News Views 8

Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...

Continue Reading
VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Updated Category News Views 5

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Continue Reading
Unicycive's Legal Turmoil: Opportunity for Investor Action

Updated Category News Views 4

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Continue Reading
Starr Conspiracy Unveils AI Tool for B2B Tech Firms

Updated Category News Views 5

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Continue Reading
Alex Jones Returns to Austin: New Studio, New Plans

Updated Category News Views 6

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

Continue Reading

Top 5 Most Recently Viewed Articles

Firstsource Solutions Earns Leadership Status in Lending Services

Updated Category News Views 117

Firstsource Solutions Limited (NSE: FSL) (BSE: 532809) made waves in the lending services sector when it was dubbed a 'Leader' in the 2024 Lending Services Operations PEAK Matrix Assessment by Everest Group. This assessment didn’t just throw around accolades; it rigorously evaluated thirty players in the field based on key metrics like market impact, strategic vision,...

Continue Reading
MoonLake Immunotherapeutics Gains Momentum with FDA Wins

Updated Category News Views 85

Introduction to MoonLake Immunotherapeutics In the current stock market, dominated by discussions on interest rate cuts and the surge in artificial intelligence, the biotechnology sector often gets overshadowed. Nevertheless, for those investors looking to explore beyond the popular tech stocks, clinical-stage biotech companies offer remarkable event-driven returns...

Continue Reading
Adalimumab Market Insights: The Enduring Rise of Humira

Updated Category News Views 63

Exploring Adalimumab Biosimilars in Modern Healthcare The field of adalimumab biosimilars is evolving rapidly, and recent insights reveal a fascinating picture. A study by Spherix Global Insights highlights that AbbVie’s Humira still holds a strong position in the market, even as biosimilars become more prevalent. Survey Findings on Healthcare Provider Attitudes A...

Continue Reading
L'OCCITANE en Provence Launches Unique Boutique on the Upper West Side

Updated Category News Views 115

L'OCCITANE en Provence Unveils Unique Boutique on the Upper West Side L'OCCITANE en Provence has launched a distinctive new boutique that celebrates its roots in the vibrant Upper West Side. Located at 416 Columbus Ave, this boutique features a thoughtful redesign aimed at capturing the essence of Provence, a region in southeastern France that is deeply connected to the...

Continue Reading
How to Find a Mortgage That Fits Your Life and Not Just Your Budget

Updated Category Real Estate Views 68

Many people begin the mortgage process by asking how much they can borrow. That feels logical, but it is usually the wrong starting point. A better question is how much you can carry comfortably without making the rest of your life feel tight every single month. Your mortgage payment is only one part of owning a home. You also need to cover property taxes, utilities, home...

Continue Reading